News & Articles

The trial will study the use of ruxolitinib, a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients

A rare lung disease drug is being trialed to help fight COVID-19

Advance your COVID-19 research with positive and negative SARS-CoV-2 samples

The study is expected to begin enrolling in June with a target of approximately 450 patients globally

Company to make the device available through broad range of healthcare, state, employer and consumer-initiated channels

The RNAdvance Viral XP is a RNA extraction kit validated for use in infectious disease and real-time PCR virus research

Thermo Scientific Orbitrap Exploris 240 mass spectrometer drives discovery and identification with quantitative precision and accuracy to meet customers' specific analytical requirements

Dr. Ofer Sharon discusses a new cancer research platform designed to improve patient outcomes, cut costs, and minimize unnecessary adverse events

Harnessing the most powerful force in the fight against disease — natural human immunity

The first 4,000 doses have been delivered for use in the Phase 2/3 clinical trial COV002 by the University of Oxford

First patients are expected to be enrolled shortly and additional European regulatory approvals are in process

People who recovered from COVID-19 shows that most individuals had generated antibodies that were intrinsically capable of neutralizing the SARS-CoV-2 virus

Cambridge Cognition has secured over $1.5 million in new contracts to support pharmaceutical clients in delivering virtual clinical trials

The cPass™ – SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit aims to detect the presence of neutralizing antibodies in an hour

Download this white paper from Sartorius to discover how enhanced data analytics and translational models can provide new biological insights

The company aims to ramp up its production capacity of more than 50 million antibody tests per month

Test will be available at NHS laboratories across the UK, using its ARCHITECT i1000SR and i2000SR and Alinity i laboratory instruments

Interim clinical study data shows ID NOW test performance of 94.7% sensitivity and 98.6% specificity

Driven by the gap in COVID-19 testing, the collaboration aims to create a fully disposable, rapid and handheld test for consumers